ZANOSAR

This brand name is authorized in United States. It is also authorized in Estonia, Finland, Japan, UK.

Active ingredients

The drug ZANOSAR contains one active pharmaceutical ingredient (API):

1	Streptozocin UNII 5W494URQ81 - STREPTOZOCIN
	Read more about Streptozocin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZANOSAR Powder for concentrate for solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01AD04	Streptozocin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AD Nitrosoureas
Discover more medicines within L01AD04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1778250, 1778531
FI	Lääkealan turvallisuus- ja kehittämiskeskus	399347
GB	Medicines & Healthcare Products Regulatory Agency	356918
JP	医薬品医療機器総合機構	4219406D1026
US	FDA, National Drug Code	0703-4636